{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T17:57:28Z","timestamp":1785434248289,"version":"3.56.0"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Manipal Academy of Higher Education - Kasturba Medical College, Mangalore"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Drug-induced eosinophilic pneumonia (EP) is an uncommon adverse drug reaction. Many drugs have been reported to cause EP, the evidence mainly being in the form of case reports\/case series. This study aims to conduct an exploratory analysis of the United States Food and Drug Administration adverse event reporting system (FAERS) database to identify previously unknown drugs that can cause EP and supplement the available evidence for known culprit drugs. A retrospective case\u2013noncase study was conducted using individual case safety reports (ICSRs) reported to the US FAERS from the first quarter of 2004 to the second quarter of 2024. Cases of potentially drug-induced EP were identified using OpenVigil application by conducting a narrow and broad scope search using the Medical Dictionary of Regulatory Activities preferred terms. A base list of drugs described in select literature to have caused EP was used to categorize known and unknown drugs. A disproportionality analysis was performed, with a reporting odds ratio\u2009&gt;\u20092, lower end of the 95% confidence interval\u2009&gt;\u20091, and a minimum of 3 reported cases considered a signal of disproportionate reporting (SDR). During the study period, 8,702,548 individual case safety reports (ICSRs) were submitted to the FAERS. Of these, 855 ICSRs using the narrow scope search and 1411 ICSRs using the broad scope search reported EP. The three most commonly reported drugs with an SDR for EP using the narrow scope search were daptomycin, naltrexone, and prednisone. The most common indications for the use of the drugs were infections, immunological conditions, asthma, and central nervous system disorders. In total, there were 45 drugs with an SDR but no supporting literature evidence available. The number of drugs implicated in causing EP has increased over the years. Several antimicrobial agents, followed by drugs affecting the central nervous system and anticancer drugs, including monoclonal antibodies, can produce EP. The list of suspected drugs identified in this study, especially those with SDR and literature evidence, should be strongly considered as a possible cause in patients presenting with pneumonia not explained otherwise.<\/jats:p>","DOI":"10.1038\/s41598-025-85681-0","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T11:54:05Z","timestamp":1736423645000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Exploratory disproportionality analysis of potentially drug-induced eosinophilic pneumonia using United States Food and Drug Administration adverse event reporting system"],"prefix":"10.1038","volume":"15","author":[{"given":"Ashwin","family":"Kamath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"key":"85681_CR1","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1055\/s-2006-939522","volume":"27","author":"J Solomon","year":"2006","unstructured":"Solomon, J. & Schwarz, M. Drug-, toxin-, and radiation therapy-induced eosinophilic pneumonia. Semin. Respir. Crit. Care Med. 27, 192\u2013197 (2006).","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"85681_CR2","doi-asserted-by":"crossref","unstructured":"Allen, J. N. Eosinophilic Pneumonia Induced by Drugs. Drug-induced and Iatrogenic Respiratory Disease (CRC, 2010).","DOI":"10.1201\/b13277-23"},{"key":"85681_CR3","unstructured":"Idiopathic acute eosinophilic. pneumonia\u2014UpToDate (2024, accessed 21 Mar 2024).  https:\/\/www.uptodate.com\/contents\/idiopathic-acute-eosinophilic-pneumonia."},{"key":"85681_CR4","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/009286150804200501","volume":"42","author":"M Lindquist","year":"2008","unstructured":"Lindquist, M. VigiBase, the WHO global ICSR database system: basic facts. Drug Inform. J. 42, 409\u2013419 (2008).","journal-title":"Drug Inform. J."},{"key":"85681_CR5","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s40264-018-0647-1","volume":"41","author":"R Postigo","year":"2018","unstructured":"Postigo, R. et al. EudraVigilance medicines safety database: publicly accessible data for research and public health protection. Drug Saf. 41, 665\u2013675 (2018).","journal-title":"Drug Saf."},{"key":"85681_CR6","unstructured":"Research, C & for DE and Questions and Answers on FDA\u2019s Adverse Event Reporting System (FAERS). FDA. FDA (2019, accessed 20 Mar 2024). https:\/\/www.fda.gov\/drugs\/surveillance\/questions-and-answers-fdas-adverse-event-reporting-system-faers."},{"key":"85681_CR7","unstructured":"Record growth pushes. VigiBase past 28 million reports. Uppsala Reports. 20211110 (2024, accessed 21 Mar 2024).  https:\/\/www.uppsalareports.org\/articles\/record-growth-pushes-vigibase-past-28-million-reports\/."},{"key":"85681_CR8","doi-asserted-by":"publisher","first-page":"e0157753","DOI":"10.1371\/journal.pone.0157753","volume":"11","author":"R B\u00f6hm","year":"2016","unstructured":"B\u00f6hm, R. et al. OpenVigil FDA\u2014inspection of U.S. American adverse drug events pharmacovigilance data and novel clinical applications. PLOS ONE  11, e0157753 (2016).","journal-title":"PLOS ONE"},{"key":"85681_CR9","unstructured":"Standardised MedDRA Queries | MedDRA [Internet] (2024, accessed 31 Mar 2024). https:\/\/www.meddra.org\/standardised-meddra-queries."},{"key":"85681_CR10","unstructured":"Research, C. & for DE and FAERS domestic and foreign reports by year. FDA (2019, accessed 21 Mar 2024). .https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/faers-domestic-and-foreign-reports-year."},{"key":"85681_CR11","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.2147\/DDDT.S81998","volume":"9","author":"K Nomura","year":"2015","unstructured":"Nomura, K. et al. Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases. Drug Des. Dev. Ther. 9, 3031\u20133041 (2015).","journal-title":"Drug Des. Dev. Ther."},{"key":"85681_CR12","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1038\/s41598-023-50013-7","volume":"14","author":"V Eshwar","year":"2024","unstructured":"Eshwar, V. & Kamath, A. Assessment of safety profile of secukinumab in real-world scenario using United States food and drug administration adverse event reporting system database. Sci. Rep. 14, 1222 (2024).","journal-title":"Sci. Rep."},{"key":"85681_CR13","doi-asserted-by":"publisher","first-page":"e9688","DOI":"10.1097\/MD.0000000000009688","volume":"97","author":"C Bartal","year":"2018","unstructured":"Bartal, C., Sagy, I. & Barski, L. Drug-induced eosinophilic pneumonia: a review of 196 case reports. Med. (Baltim). 97, e9688 (2018).","journal-title":"Med. (Baltim)."},{"key":"85681_CR14","unstructured":"Camus, P., Bonniaud, P., Camus, C., Foucher, P. & Jacquet, L. Pneumotox\u2014an updated time-saving web resource. Eur. Respir. J. 2013, 42. https:\/\/erj.ersjournals.com\/content\/42\/Suppl_57\/5043 (2013)."},{"key":"85681_CR15","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12890-019-0800-3","volume":"19","author":"K Ota","year":"2019","unstructured":"Ota, K. et al. Age distribution and seasonality in acute eosinophilic pneumonia: analysis using a national inpatient database. BMC Pulm. Med. 19, 38 (2019).","journal-title":"BMC Pulm. Med."},{"key":"85681_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13756-016-0158-8","volume":"5","author":"P Uppal","year":"2016","unstructured":"Uppal, P., LaPlante, K. L., Gaitanis, M. M., Jankowich, M. D. & Ward, K. E. Daptomycin-induced eosinophilic pneumonia\u2014a systematic review. Antimicrob. Resist. Infect. Control 5, 55 (2016).","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"85681_CR17","unstructured":"Research, C. & for DE and FDA drug safety communication: eosinophilic pneumonia associated with the use of cubicin (daptomycin). FDA  (2019, accessed 4 Jun 2024). https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/fda-drug-safety-communication-eosinophilic-pneumonia-associated-use-cubicin-daptomycin."},{"key":"85681_CR18","first-page":"12","volume":"24","author":"N Hosogaya","year":"2018","unstructured":"Hosogaya, N., Toida, K., Ishihara, H. & Kugiyama, K. A case of drug induced lung injury caused by levofloxacin eye drops. Respir Med. Case Rep. 24, 12\u201315 (2018).","journal-title":"Respir Med. Case Rep."},{"key":"85681_CR19","unstructured":"DUPIXENT Injection  (2024, accessed 4 Jun 2024). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/761055Orig1s000TOC.cfm."},{"key":"85681_CR20","doi-asserted-by":"publisher","first-page":"e243881","DOI":"10.1136\/bcr-2021-243881","volume":"14","author":"D LaMorte","year":"2021","unstructured":"LaMorte, D., Desmond, D., Ellis, J. & Lipkowitz, S. Acute eosinophilic pneumonia: a fatal reaction to ado-trastuzumab. BMJ Case Rep. 14, e243881 (2021).","journal-title":"BMJ Case Rep."},{"key":"85681_CR21","doi-asserted-by":"publisher","first-page":"550","DOI":"10.2169\/internalmedicine.33.550","volume":"33","author":"O Sakito","year":"1994","unstructured":"Sakito, O. et al. Pulmonary infiltration with eosinophilia and increased serum levels of squamous cell carcinoma-related antigen and neuron specific enolase. Intern. Med. 33, 550\u2013553 (1994).","journal-title":"Intern. Med."},{"key":"85681_CR22","first-page":"70","volume":"3","author":"O Matsuno","year":"2007","unstructured":"Matsuno, O., Takenaka, R., Ando, M., Miyazaki, E. & Kumamoto, T. Amoxicillin-induced eosinophilic pneumonia with granulomatous reaction: discrepancy between drug-induced lymphocyte stimulation test findings and the provocation drug test. Allergy Asthma Clin. Immunol. 3, 70\u201372 (2007).","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"85681_CR23","first-page":"e41646","volume":"15","author":"J Oh","year":"2023","unstructured":"Oh, J., Singh, A., Fonseca, M. & Muppidi, M. A case of Amoxicillin-Induced drug reaction with Eosinophilia and systemic symptoms (Dress) Syndrome Associated with significant reactive hypereosinophilia (HE): a case report. Cureus 15, e41646 (2023).","journal-title":"Cureus"},{"key":"85681_CR24","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.rmr.2021.03.010","volume":"38","author":"A Van Oortegem","year":"2021","unstructured":"Van Oortegem, A., Meurice, J-C., Verdaguer, M. & Bironneau, V. Case report of severe acute eosinophilic pneumonia induced by Amoxicillin. Rev. Mal. Respir.  38, 524\u2013529 (2021).","journal-title":"Rev. Mal. Respir."},{"key":"85681_CR25","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/bcp.13096","volume":"83","author":"E Ram\u00edrez","year":"2017","unstructured":"Ram\u00edrez, E. et al. Eosinophilic drug reactions detected by a prospective pharmacovigilance programme in a tertiary hospital. Br. J. Clin. Pharmacol. 83, 400\u2013415 (2017).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"85681_CR26","doi-asserted-by":"publisher","unstructured":"Devarajan, A. & Azadeh, N. A rare case of capecitabine superimposed with adalimumab: drug induced eosinophilic pneumonia. A37 case reports: drug toxicity. American Thoracic Society, pp. A1396\u2013A1396 (2022, accessed 2 Dec 2024). https:\/\/www.atsjournals.org\/doi\/abs\/, https:\/\/doi.org\/10.1164\/ajrccm-conference.2022.205.1_MeetingAbstracts.A1396.","DOI":"10.1164\/ajrccm-conference.2022.205.1_MeetingAbstracts.A1396"},{"key":"85681_CR27","doi-asserted-by":"publisher","first-page":"A3407","DOI":"10.1016\/j.chest.2023.07.2215","volume":"164","author":"C Nguyen","year":"2023","unstructured":"Nguyen, C. et al. A rare case of acute eosinophilic pneumonia from carfilzomib. CHEST 164, A3407\u2013A3408 (2023).","journal-title":"CHEST"},{"key":"85681_CR28","doi-asserted-by":"publisher","first-page":"e01166","DOI":"10.1016\/j.idcr.2021.e01166","volume":"25","author":"BM Jones","year":"2021","unstructured":"Jones, B. M., Murray, E. Y., Crosby, C., Rojas, S. & Bland, C. M. Eosinophilic pneumonia caused by cefepime: a case report and review. IDCases 25, e01166 (2021).","journal-title":"IDCases"},{"key":"85681_CR29","doi-asserted-by":"publisher","first-page":"72","DOI":"10.4103\/2279-042X.137077","volume":"3","author":"VS Guleria","year":"2014","unstructured":"Guleria, V. S., Dhillon, M., Gill, S. & Naithani, N. Ceftriaxone induced drug rash with eosinophilia and systemic symptoms. J. Res. Pharm. Pract. 3, 72\u201374 (2014).","journal-title":"J. Res. Pharm. Pract."},{"key":"85681_CR30","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1016\/j.jinf.2005.10.028","volume":"53","author":"FZ Akcam","year":"2006","unstructured":"Akcam, F. Z., Aygun, F. O. & Akkaya, V. B. DRESS like severe drug rash with eosinophilia, atypic lymphocytosis and fever secondary to ceftriaxone. J. Infect. 53, e51\u201353 (2006).","journal-title":"J. Infect."},{"key":"85681_CR31","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1183\/09031936.03.00057903","volume":"23","author":"D Steiger","year":"2003","unstructured":"Steiger, D., Bubendorf, L., Oberholzer, M., Tamm, M. & Leuppi, J. D. Ciprofloxacin-induced acute interstitial pneumonitis. Eur. Respir. J. 23, 172\u2013174 (2003).","journal-title":"Eur. Respir. J."},{"key":"85681_CR32","doi-asserted-by":"crossref","unstructured":"Torre, M. D., Vitale, C. & Caliandro, D. The consequences of not looking at the eosinophil count: pulmonary infiltrates and eosinophilia syndrome (PIE) probably caused by ciprofloxacin. Eur. J. Case Rep. Internal Med. 2015, 2. https:\/\/www.ejcrim.com\/index.php\/EJCRIM\/article\/view\/201  (2015).","DOI":"10.12890\/2015_000201"},{"key":"85681_CR33","first-page":"243","volume":"54","author":"A Celandroni","year":"2002","unstructured":"Celandroni, A., Cinquanta, L., Lagrasta, U. E. & Caprai, S. Loeffler syndrome and Mycoplasma pneumonitis. A case report. Minerva Pediatr. 54, 243\u2013247 (2002).","journal-title":"Minerva Pediatr."},{"key":"85681_CR34","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/1475-2875-12-241","volume":"12","author":"T Rolling","year":"2013","unstructured":"Rolling, T. et al. Artesunate versus quinine in the treatment of severe imported malaria: comparative analysis of adverse events focussing on delayed haemolysis. Malar. J. 12, 241 (2013).","journal-title":"Malar. J."},{"key":"85681_CR35","doi-asserted-by":"publisher","first-page":"248","DOI":"10.2169\/internalmedicine1962.29.248","volume":"29","author":"S Kohno","year":"1990","unstructured":"Kohno, S. et al. Clinical evaluation of 12 cases of antimicrobial drug-induced pneumonitis. Jpn. J. Med. 29, 248\u2013254 (1990).","journal-title":"Jpn. J. Med."},{"key":"85681_CR36","doi-asserted-by":"publisher","first-page":"e00541","DOI":"10.1002\/rcr2.541","volume":"8","author":"Y Inagaki","year":"2020","unstructured":"Inagaki, Y., Tachibana, K., Inoue, Y., Kasai, T. & Inoue, Y. Severe clopidogrel-induced DRESS with eosinophilic pneumonia associated with Epstein-Barr virus reactivation. Respirol. Case Rep. 8, e00541 (2020).","journal-title":"Respirol. Case Rep."},{"key":"85681_CR37","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.2169\/internalmedicine.9028-21","volume":"61","author":"A Takemasa","year":"2022","unstructured":"Takemasa, A. Clopidogrel-induced Eosinophilia and Hypercalcemia with multiple organ lesions including eosinophilic pneumonia. Intern. Med. 61, 2559\u20132560 (2022).","journal-title":"Intern. Med."},{"key":"85681_CR38","doi-asserted-by":"publisher","unstructured":"Nelson, M., Hoof, P. & Mora, A. A case of systemic hypereosinophilia associated with doxycycline administration. C43 drug induced lung disease: case reports. American Thoracic Society, pp. A5574\u2013A5574 (2017, accessed 30 May 2024). https:\/\/www.atsjournals.org\/doi\/abs\/, https:\/\/doi.org\/10.1164\/ajrccm-conference.2017.195.1_MeetingAbstracts.A5574.","DOI":"10.1164\/ajrccm-conference.2017.195.1_MeetingAbstracts.A5574"},{"key":"85681_CR39","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.annder.2009.10.180","volume":"137","author":"C Mailhol","year":"2010","unstructured":"Mailhol, C. et al. [Severe drug hypersensitivity reaction (DRESS syndrome) to doxycycline]. Ann. Dermatol. Venereol. 137, 40\u201343 (2010).","journal-title":"Ann. Dermatol. Venereol."},{"key":"85681_CR40","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1159\/000056325","volume":"69","author":"S Pesenti","year":"2002","unstructured":"Pesenti, S. et al. Diffuse infiltrative lung disease associated with flecainide. Report of two cases. Respiration 69, 182\u2013185 (2002).","journal-title":"Respiration"},{"key":"85681_CR41","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1186\/s13256-022-03619-w","volume":"16","author":"G Moureau","year":"2022","unstructured":"Moureau, G. et al. Flecainide-induced pneumonitis: a case report. J. Med. Case Rep. 16, 404 (2022).","journal-title":"J. Med. Case Rep."},{"key":"85681_CR42","first-page":"518","volume":"49","author":"JF Viallard","year":"1994","unstructured":"Viallard, J. F., Neau, D., Monlun, E., Longy-Boursier, M. & Le Bras, M. Hypereosinophilia associated with heparin: a case with a challenge test. Therapie 49, 518 (1994).","journal-title":"Therapie"},{"key":"85681_CR43","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1600-0536.2010.01784.x","volume":"64","author":"K Klos","year":"2011","unstructured":"Klos, K., Spiewak, R., Kruszewski, J. & Bant, A. Cutaneous adverse drug reaction to heparins with hypereosinophilia and high IgE level. Contact Dermat. 64, 61\u201362 (2011).","journal-title":"Contact Dermat."},{"key":"85681_CR44","doi-asserted-by":"publisher","first-page":"e356","DOI":"10.1111\/1346-8138.14905","volume":"46","author":"Y Ishiguro","year":"2019","unstructured":"Ishiguro, Y. et al. Drug-induced acute eosinophilic pneumonia due to hydroxychloroquine in a chilblain lupus patient. J. Dermatol. 46, e356\u2013e357 (2019).","journal-title":"J. Dermatol."},{"key":"85681_CR45","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1513\/AnnalsATS.201407-306CC","volume":"11","author":"JA Hamilton","year":"2014","unstructured":"Hamilton, J. A. & Bishop, J. M. 69-year-old woman with rheumatoid arthritis presents with shortness of breath and cough. Ann. Am. Thorac. Soc. 11, 1653\u20131655 (2014).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"85681_CR46","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3109\/s10165-005-0387-9","volume":"15","author":"F Sakai","year":"2005","unstructured":"Sakai, F. et al. Leflunomide-related lung injury in patients with rheumatoid arthritis: imaging features. Mod. Rheumatol. 15, 173\u2013179 (2005).","journal-title":"Mod. Rheumatol."},{"key":"85681_CR47","first-page":"385","volume":"38","author":"K Fujimori","year":"2000","unstructured":"Fujimori, K., Shimatsu, Y., Suzuki, E., Arakawa, M. & Gejyo, F. Levofloxacin-induced eosinophilic pneumonia complicated by bronchial asthma. Nihon Kokyuki Gakkai Zasshi 38, 385\u2013390 (2000).","journal-title":"Nihon Kokyuki Gakkai Zasshi"},{"key":"85681_CR48","doi-asserted-by":"publisher","unstructured":"Salimnia, T., Peterson, D., Ralh, N. & Johnson, L. B. Linezolid induced interstitial lung disease. D38 lung transplantation and drug related case reports. American Thoracic Society, pp. A6278\u2013A6278. (2019, accessed 30 May 2024). https:\/\/www.atsjournals.org\/doi\/abs\/, https:\/\/doi.org\/10.1164\/ajrccm-conference.2019.199.1_MeetingAbstracts.A6278.","DOI":"10.1164\/ajrccm-conference.2019.199.1_MeetingAbstracts.A6278"},{"key":"85681_CR49","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1053\/j.ajkd.2009.07.013","volume":"54","author":"S Savard","year":"2009","unstructured":"Savard, S., Desmeules, S., Riopel, J. & Agharazii, M. Linezolid-Associated Acute interstitial nephritis and drug Rash with Eosinophilia and systemic symptoms (DRESS) syndrome. Am. J. Kidney Dis. 54, e17\u201320 (2009).","journal-title":"Am. J. Kidney Dis."},{"key":"85681_CR50","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1159\/000509789","volume":"50","author":"Q-D Hu","year":"2021","unstructured":"Hu, Q-D., Mao, N., Huang, X-C., Chen, D-G. & Zhang, Q. Identification of complex pneumonia during the outbreak of COVID-19: bacterial pneumonia combined with acute eosinophilic pneumonia in patients with maintenance hemodialysis. Blood Purif. 50, 132\u2013136 (2021).","journal-title":"Blood Purif."},{"key":"85681_CR51","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40792-020-00803-2","volume":"6","author":"Y Goda","year":"2020","unstructured":"Goda, Y., Shoji, T. & Katakura, H. Unilateral antibiotic-induced acute eosinophilic pneumonia on the operative side after surgery for primary lung cancer: a case report. Surg. Case Rep. 6, 40 (2020).","journal-title":"Surg. Case Rep."},{"key":"85681_CR52","doi-asserted-by":"publisher","first-page":"461","DOI":"10.4103\/lungindia.lungindia_328_16","volume":"34","author":"NA Hatem","year":"2017","unstructured":"Hatem, N. A., Campbell, S., Rubio, E. & Loschner, A. L. Meropenem: a possible new culprit in eosinophilic lung diseases. Lung India 34, 461\u2013464 (2017).","journal-title":"Lung India"},{"key":"85681_CR53","first-page":"511","volume":"44","author":"A\u0130 \u00c7elik","year":"2016","unstructured":"\u00c7elik, A. \u0130., Deniz, A., Tangalay, M., Karaaslan, M. B. & Ba\u011f\u0131r K\u0131l\u0131\u00e7, E. Eosinophilic myocarditis associated with eosinophilic pneumonia and eosinophilia following antibiotic and narcotic analgesic treatment. Turk. Kardiyol Dern Ars. 44, 511\u2013513 (2016).","journal-title":"Turk. Kardiyol Dern Ars"},{"key":"85681_CR54","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1001\/jama.1988.03410020044028","volume":"260","author":"M Kristenson","year":"1988","unstructured":"Kristenson, M. & Fryd\u00e9n, A. Pneumonitis caused by metronidazole. JAMA 260, 184 (1988).","journal-title":"JAMA"},{"key":"85681_CR55","doi-asserted-by":"publisher","unstructured":"Johnson, K. & Nasser, W.  A common drug with an uncommon complication. A48 conventional drug associated lung disease. American Thoracic Society, pp. A1666\u2013A1666. (2016, accessed 2 Dec 2024). https:\/\/www.atsjournals.org\/doi\/abs\/, https:\/\/doi.org\/10.1164\/ajrccm-conference.2016.193.1_MeetingAbstracts.A1666  (2016).","DOI":"10.1164\/ajrccm-conference.2016.193.1_MeetingAbstracts.A1666"},{"key":"85681_CR56","first-page":"113","volume":"61","author":"MA Man","year":"2012","unstructured":"Man, M. A., Alexandrescu, D., Pop, M. & Trofor, A. Churg Strauss syndrome associated with montelukast\u2013case report. Pneumologia 61, 113\u2013116 (2012).","journal-title":"Pneumologia"},{"key":"85681_CR57","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1080\/02770900903006273","volume":"46","author":"DM Kaliterna","year":"2009","unstructured":"Kaliterna, D. M., Perkovi\u0107, D. & Radi\u0107, M. Churg-Strauss syndrome associated with montelukast therapy. J. Asthma  46, 604\u2013605 (2009).","journal-title":"J. Asthma"},{"key":"85681_CR58","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1093\/ndt\/15.7.1054","volume":"15","author":"LG G\u00f8ransson","year":"2000","unstructured":"G\u00f8ransson, L. G. & Omdal, R. A severe systemic inflammatory reaction following therapy with montelukast (singulair). Nephrol. Dial Transpl. 15, 1054\u20131055 (2000).","journal-title":"Nephrol. Dial Transpl."},{"key":"85681_CR59","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1136\/thx.54.6.558","volume":"54","author":"J Franco","year":"1999","unstructured":"Franco, J. & Art\u00e9s, M. J. Pulmonary eosinophilia associated with montelukast. Thorax 54, 558\u2013560 (1999).","journal-title":"Thorax"},{"key":"85681_CR60","first-page":"e50621","volume":"15","author":"A Schuldt","year":"2023","unstructured":"Schuldt, A., Najmuddin, A., Sharma, M. & Surani, S. A case of Chronic Eosinophilic Pneumonia Associated with the use of weight loss combination medication naltrexone-bupropion. Cureus 15, e50621 (2023).","journal-title":"Cureus"},{"key":"85681_CR61","first-page":"e10221","volume":"12","author":"PR Korpole","year":"2020","unstructured":"Korpole, P. R., Al-Bacha, S. & Hamadeh, S. A case for biopsy: injectable naltrexone-induced acute eosinophilic pneumonia. Cureus 12, e10221 (2020).","journal-title":"Cureus"},{"key":"85681_CR62","doi-asserted-by":"publisher","first-page":"e32473","DOI":"10.1097\/MD.0000000000032473","volume":"102","author":"A Vivien","year":"2023","unstructured":"Vivien, A. et al. Pomalidomide-induced lung injury: a case report. Med. (Baltim). 102, e32473 (2023).","journal-title":"Med. (Baltim)."},{"key":"85681_CR63","doi-asserted-by":"publisher","unstructured":"Carter, D., Ellaicy, O., Distel, C. & Khan, M. A case of pomalidomide induced acute eosinophilic pneumonia. B54 case reports in oncologic treatment-related lung disease. American Thoracic Society,  pp. A3853\u2013A3853. (2024, accessed 2 Dec 2024). https:\/\/www.atsjournals.org\/doi\/abs\/ (2024). https:\/\/doi.org\/10.1164\/ajrccm-conference.2024.209.1_MeetingAbstracts.A3853.","DOI":"10.1164\/ajrccm-conference.2024.209.1_MeetingAbstracts.A3853"},{"key":"85681_CR64","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1159\/000074216","volume":"70","author":"J-I Ashitani","year":"2003","unstructured":"Ashitani, J-I., Yanagi, S., Arimura, Y., Sano, A. & Mukae, H. Acute respiratory distress syndrome induced by rifampicin with high levels of neutrophil and eosinophil products in bronchoalveolar lavage fluid. Respiration 70, 541\u2013543 (2003).","journal-title":"Respiration"},{"key":"85681_CR65","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1136\/thorax.57.11.1000","volume":"57","author":"N Kunichika","year":"2002","unstructured":"Kunichika, N. et al. Pneumonitis induced by rifampicin. Thorax 57, 1000\u20131001 (2002).","journal-title":"Thorax"},{"key":"85681_CR66","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.aller.2013.08.003","volume":"43","author":"YH Nam","year":"2015","unstructured":"Nam, Y. H. et al. Drug reaction with eosinophilia and systemic symptoms syndrome is not uncommon and shows better clinical outcome than generally recognised. Allergol. Immunopathol. (Madr.) 43, 19\u201324 (2015).","journal-title":"Allergol. Immunopathol. (Madr.)"},{"key":"85681_CR67","first-page":"101496","volume":"34","author":"F Nasim","year":"2021","unstructured":"Nasim, F., Paul, J. A., Boland-Froemming, J. & Wylam, M. E. Sulfa-induced acute eosinophilic pneumonia. Respir. Med. Case Rep. 34, 101496 (2021).","journal-title":"Respir. Med. Case Rep."},{"key":"85681_CR68","first-page":"101632","volume":"37","author":"Y Mochizuka","year":"2022","unstructured":"Mochizuka, Y. et al. Trimethoprim-sulfamethoxazole induced eosinophilic pneumonia: a case report. Respir Med. Case Rep. 37, 101632 (2022).","journal-title":"Respir Med. Case Rep."},{"key":"85681_CR69","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.anai.2018.12.007","volume":"122","author":"I Garc\u00eda-Moguel","year":"2019","unstructured":"Garc\u00eda-Moguel, I., Bobolea, I., Di\u00e9guez Pastor, M. C., L\u00f3pez-Arranz Monge, G. & Barranco Jimenez, R. Acute eosinophilic pneumonia due to piperacillin\/tazobactam. Ann. Allergy Asthma Immunol. 122, 334\u2013336 (2019).","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"85681_CR70","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.12659\/AJCR.917647","volume":"20","author":"T Isono","year":"2019","unstructured":"Isono, T., Sawaguchi, H., Kusumoto, H. & Shiono, H. Eosinophilic pneumonia putatively induced by vancomycin: a case report. Am. J. Case Rep. 20, 1440\u20131445 (2019).","journal-title":"Am. J. Case Rep."},{"key":"85681_CR71","first-page":"1208","volume":"54","author":"T Sato","year":"2005","unstructured":"Sato, T., Hagiwara, K., Matsuno, H. & Akiyama, O. Case of congestive heart failure associated with hypereosinophilia developed during antibiotics treatment. Arerugi 54, 1208\u20131212 (2005).","journal-title":"Arerugi"},{"key":"85681_CR72","doi-asserted-by":"publisher","first-page":"e14017","DOI":"10.1097\/MD.0000000000014017","volume":"98","author":"F Jin","year":"2019","unstructured":"Jin, F. & Wang, S-T. Chronic eosinophilic pneumonia after trastuzumab and radiation therapy for breast cancer: a case report. Med. (Baltim). 98, e14017 (2019).","journal-title":"Med. (Baltim)."},{"key":"85681_CR73","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s10549-008-9966-8","volume":"113","author":"MJ Pepels","year":"2009","unstructured":"Pepels, M. J., Boomars, K. A., van Kimmenade, R. & Hupperets, P. S. Life-threatening interstitial lung disease associated with trastuzumab: case report. Breast Cancer Res. Treat. 113, 609\u2013612 (2009).","journal-title":"Breast Cancer Res. Treat."},{"key":"85681_CR74","doi-asserted-by":"publisher","first-page":"477","DOI":"10.4103\/ijn.IJN_166_17","volume":"28","author":"T Aatif","year":"2018","unstructured":"Aatif, T., Fatihi, J., El Annaz, H. & Qamouss, O. Allopurinol-induced drug reactions with Eosinophilia and systemic symptoms syndrome with interstitial nephritis. Indian J. Nephrol. 28, 477\u2013481 (2018).","journal-title":"Indian J. Nephrol."},{"key":"85681_CR75","doi-asserted-by":"publisher","first-page":"772A","DOI":"10.1016\/j.chest.2016.08.868","volume":"150","author":"F Siddiqui","year":"2016","unstructured":"Siddiqui, F., Siddiqui, A. H., Khan, T., Ansari, Y. & Chalhoub, M. Allopurinol and the lung. CHEST 150, 772A (2016).","journal-title":"CHEST"},{"key":"85681_CR76","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3349\/ymj.2001.42.3.357","volume":"42","author":"H Noh","year":"2001","unstructured":"Noh, H. et al. Acute eosinophilic pneumonia associated with Amitriptyline in a hemodialysis patient. Yonsei Med. J. 42, 357\u2013359 (2001).","journal-title":"Yonsei Med. J."},{"key":"85681_CR77","doi-asserted-by":"publisher","first-page":"529","DOI":"10.5217\/ir.2017.15.4.529","volume":"15","author":"J Yeo","year":"2017","unstructured":"Yeo, J. et al. Drug-induced eosinophilic pneumonia in a patient with Crohn\u2019s disease: diagnosis and treatment using fraction of exhaled nitric oxide. Intest Res. 15, 529\u2013534 (2017).","journal-title":"Intest Res."},{"key":"85681_CR78","first-page":"290","volume":"70","author":"S Katsenos","year":"2007","unstructured":"Katsenos, S. et al. Drug-induced pulmonary toxicity in a patient treated with mesalazine and azathioprine for ulcerative colitis. Acta Gastroenterol. Belg. 70, 290\u2013292 (2007).","journal-title":"Acta Gastroenterol. Belg."},{"key":"85681_CR79","unstructured":"Aronson, J. K.Biotin. Meyler\u2019s side effects of drugs (Sixteenth Edition), Elsevier, pp. 988.  (2024, accessed 31 May 31 2024) . https:\/\/www.sciencedirect.com\/science\/article\/pii\/B9780444537171003851."},{"key":"85681_CR80","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1345\/aph.10213","volume":"35","author":"PM Debourdeau","year":"2001","unstructured":"Debourdeau, P. M. et al. Life-threatening eosinophilic pleuropericardial effusion related to vitamins B5 and H. Ann. Pharmacother. 35, 424\u2013426 (2001).","journal-title":"Ann. Pharmacother"},{"key":"85681_CR81","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1097\/YIC.0000000000000311","volume":"35","author":"M Nakamura","year":"2020","unstructured":"Nakamura, M. & Nagamine, T. Eosinophilic pneumonia during treatment with clozapine: reports from a retrospective case series. Int. Clin. Psychopharmacol. 35, 285\u2013291 (2020).","journal-title":"Int. Clin. Psychopharmacol."},{"key":"85681_CR82","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ajp.2019.07.009","volume":"44","author":"M Nakamura","year":"2019","unstructured":"Nakamura, M. & Nagamine, T. Recurrence of eosinophilic pneumonia after clozapine treatment. Asian J. Psychiatr. 44, 4\u20135 (2019).","journal-title":"Asian J. Psychiatr"},{"key":"85681_CR83","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/JCP.0000000000000256","volume":"35","author":"N Hashimoto","year":"2015","unstructured":"Hashimoto, N., Maeda, T., Okubo, R., Narita, H. & Kusumi, I. Simple pulmonary eosinophilia associated with clozapine treatment. J. Clin. Psychopharmacol. 35, 99\u2013101 (2015).","journal-title":"J. Clin. Psychopharmacol."},{"key":"85681_CR84","first-page":"101968","volume":"47","author":"D Nakashima","year":"2024","unstructured":"Nakashima, D., Mori, E. & Otori, N. A case of recurrent chronic eosinophilic pneumonia after switching from benralizumab to dupilumab. Respir Med. Case Rep. 47, 101968 (2024).","journal-title":"Respir Med. Case Rep."},{"key":"85681_CR85","doi-asserted-by":"publisher","first-page":"1277734","DOI":"10.3389\/fimmu.2023.1277734","volume":"14","author":"X Zhou","year":"2023","unstructured":"Zhou, X. et al. Dupilumab and the potential risk of eosinophilic pneumonia: case report, literature review, and FAERS database analysis. Front. Immunol. 14, 1277734 (2023).","journal-title":"Front. Immunol."},{"key":"85681_CR86","first-page":"202","volume":"62","author":"P Kemp","year":"2024","unstructured":"Kemp, P. et al. Hypereosinophilia during dupilumab treatment in patients with chronic rhinosinusitis with nasal polyps. Rhinology 62, 202\u2013207 (2024).","journal-title":"Rhinology"},{"key":"85681_CR87","doi-asserted-by":"crossref","unstructured":"Kurihara, M. et al. How can: dupilumab cause eosinophilic pneumonia? Biomolecules  12, 1743  (2022).","DOI":"10.3390\/biom12121743"},{"key":"85681_CR88","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S0151-9638(06)70992-9","volume":"133","author":"P Le Nouail","year":"2006","unstructured":"Le Nouail, P. et al. Drug reaction with eosinophilia and systemic symptoms (DRESS) following imatinib therapy. Ann. Dermatol. Venereol. 133, 686\u2013688 (2006).","journal-title":"Ann. Dermatol. Venereol."},{"key":"85681_CR89","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1038\/sj.leu.2404207","volume":"20","author":"K Ohnishi","year":"2006","unstructured":"Ohnishi, K., Sakai, F., Kudoh, S. & Ohno, R. Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate. Leukemia 20, 1162\u20131164 (2006).","journal-title":"Leukemia"},{"key":"85681_CR90","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s12185-010-0729-z","volume":"92","author":"K Suemori","year":"2010","unstructured":"Suemori, K., Fujiwara, H., Watanabe, S., Azuma, T. & Yasukawa, M. A case of chronic myeloid leukemia with eosinophilic interstitial pneumonitis after administration of imatinib mesylate for 11 months. Int. J. Hematol. 92, 777\u2013778 (2010).","journal-title":"Int. J. Hematol."},{"key":"85681_CR91","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40360-017-0121-1","volume":"18","author":"P Gaspar-da-Costa","year":"2017","unstructured":"Gaspar-da-Costa, P. et al. Methimazole associated eosinophilic pleural effusion: a case report. BMC Pharmacol. Toxicol. 18, 16 (2017).","journal-title":"BMC Pharmacol. Toxicol."},{"key":"85681_CR92","doi-asserted-by":"crossref","unstructured":"Huang, C-C., Kuo, S-C., Chen, C-Y. & Yeh, Y-W. Hypereosinophilia and cognitive impairment induced by mirtazapine. Am. J. Ther. (2023).","DOI":"10.1097\/MJT.0000000000001632"},{"key":"85681_CR93","doi-asserted-by":"publisher","first-page":"740182","DOI":"10.3389\/fmed.2022.740182","volume":"9","author":"W-Y Kuo","year":"2022","unstructured":"Kuo, W-Y. et al. Antidepressants usage and risk of pneumonia among elderly patients with the Parkinson\u2019s disease: a population-based case-control study. Front. Med. (Lausanne) 9, 740182 (2022).","journal-title":"Front. Med. (Lausanne)"},{"key":"85681_CR94","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1111\/j.1398-9995.2009.02061.x","volume":"64","author":"M Cazzola","year":"2009","unstructured":"Cazzola, M., Mura, M., Segreti, A., Mattei, M. A. & Rogliani, P. Eosinophilic pneumonia in an asthmatic patient treated with omalizumab therapy: forme-fruste of Churg-Strauss syndrome? Allergy 64, 1389\u20131390 (2009).","journal-title":"Allergy"},{"key":"85681_CR95","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1016\/S0221-0363(09)73273-1","volume":"90","author":"D Szwarc","year":"2009","unstructured":"Szwarc, D. et al. Churg-Strauss syndrome under omalizumab treatment: a rare visceral manifestation. J. Radiol. 90, 1737\u20131739 (2009).","journal-title":"J. Radiol."},{"key":"85681_CR96","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.jaci.2007.10.040","volume":"121","author":"A-M Ruppert","year":"2008","unstructured":"Ruppert, A-M. et al. Development of Churg-Strauss syndrome with controlled asthma during omalizumab treatment. J. Allergy Clin. Immunol. 121, 253\u2013254 (2008).","journal-title":"J. Allergy Clin. Immunol."},{"key":"85681_CR97","doi-asserted-by":"publisher","first-page":"e240078","DOI":"10.1136\/bcr-2020-240078","volume":"14","author":"LN Carson","year":"2021","unstructured":"Carson, L. N., Pradhan, A. & Subramanian, D. Omalizumab-associated eosinophilic granulomatosis with polyangiitis: cause or coincidence? BMJ Case Rep. 14, e240078 (2021).","journal-title":"BMJ Case Rep."},{"key":"85681_CR98","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.jaclp.2022.02.010","volume":"63","author":"L de Ghellinck","year":"2022","unstructured":"de Ghellinck, L., Frusch, N. & Duysinx, B. Eosinophilic pleural effusion induced by paliperidone palmitate: case report and literature review. J. Acad. Consult Liaison Psychiatry 63, 394\u2013399 (2022).","journal-title":"J. Acad. Consult Liaison Psychiatry"},{"key":"85681_CR99","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1001\/jama.279.6.455","volume":"279","author":"ME Wechsler","year":"1998","unstructured":"Wechsler, M. E. et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA 279, 455\u2013457 (1998).","journal-title":"JAMA"},{"key":"85681_CR100","first-page":"275","volume":"98","author":"J Holloway","year":"1998","unstructured":"Holloway, J., Ferriss, J., Groff, J., Craig, T. J. & Klinek, M. Churg-Strauss syndrome associated with zafirlukast. J. Am. Osteopath. Assoc. 98, 275\u2013278 (1998).","journal-title":"J. Am. Osteopath. Assoc."},{"key":"85681_CR101","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1378\/chest.114.1.332","volume":"114","author":"DL Knoell","year":"1998","unstructured":"Knoell, D. L., Lucas, J. & Allen, J. N. Churg-Strauss syndrome associated with zafirlukast. Chest 114, 332\u2013334 (1998).","journal-title":"Chest"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85681-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85681-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85681-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T13:04:21Z","timestamp":1736427861000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85681-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":101,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["85681"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-85681-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,9]]},"assertion":[{"value":"13 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.K. is an editorial board member of Scientific Reports journal. The author has no other competing interests to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study adhered to relevant guidelines and regulations. The study was approved by Institutional Ethics Committee, Kasturba Medical College, Mangalore (IEC KMC MLR 04\/2024\/225). Informed consent was waived by Institutional Ethics Committee, Kasturba Medical College, Mangalore.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"1455"}}